Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year

Journal of Clinical Psychiatry

Volumn 67, Issue 8, 2006, Pages 1171-1178

  Merrill, Charley A ^a   Jonsson, Michael A G ^b   Minthon, Lennart ^c   Ejnell, Hasse ^d   Silander, Hans C Son ^d   Blennow, Kaj ^b   Karlsson, Mats ^c   Nordlund, Arto ^b   Rolstad, Sindre ^b   Warkentin, Siegbert ^c   Ben Menachem, Elinor ^b   Sjögren, Magnus J C ^e,f  

^a FOREST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; NEUROLEPTIC AGENT; RIVASTIGMINE; TACRINE; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIORAL SCIENCE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DEPRESSION; DEVICE; DRUG MECHANISM; DYSPHAGIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOBAL CHANGE; HOARSENESS; HUMAN; IMPLANTATION; MALE; MINI MENTAL STATE EXAMINATION; MOOD CHANGE; PAIN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; VAGUS NERVE STIMULATION; VOICE CHANGE;

EID: 33748961626     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0801     Document Type: Article

References (48)

1. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-1122
2. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989;262:2551-2556
3. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1261-1264
4. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994;271:985-991
5. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65
6. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999;318:633-638
7. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-2276
8. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145
9. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341
10. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-324
11. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094-2103
12. Sjogren M, Andreasen N, Blennow K. Advances in the detection of Alzheimer's disease: use of cerebrospinal fluid biomarkers. Clin Chim Acta 2003;332:1-10
13. Sjogren M, Davidsson P, Gottfries J. et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord 2001;12:257-264
14. Sjogren M, Minthon L, Davidsson P, et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000;107:563-579
15. Sunderland T, Wolozin B, Galasko D, et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry 1999;46:750-755
16. Andreasen N, Minthon L, Clarberg A, et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999;53:1488-1494
17. Andreasen N, Minthon L, Vanmechelen E, et al. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999;273:5-8
18. Bartus RT, Dean RL III, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-414
19. Lyness SA, Zarow C, Chui HC. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging 2003;24:1-23
20. Matthews KL, Chen CP, Esiri MM, et al. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry 2002;51:407-416
21. Gottfries CG. Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia. J Neural Transm Suppl 1990:30:33-43
22. Naritoku DK, Terry WJ, Helfert RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. Epilepsy Res 1995;22:53-62
23. Hassert DL, Miyashita T, Williams CL. The effects of peripheral vagal nerve stimulation at a memory-modulating intensity on norepinephrine output in the basolateral amygdala. Behav Neurosci 2004;118:79-88
24. Kling MA, Loyd D, Sansbury N, et al. Effects of short-term VNS therapy on fos expression in rat brain nuclei. Presented at the 59th Annual Scientific Convention of The Society of Biological Psychiatry; May 15-17, 2003; San Francisco, Calif
25. Sjögren MJ, Hellstrom PT, Jonsson MA, et al. Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study. J Clin Psychiatry 2002;63:972-980
26. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984:34:939-944
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
28. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. Geneva, Switzerland: World Health Organization; 1992
29. Wallin A, Brun A, Gustafson L. Swedish consensus on dementia diseases. Acta Neurol Scand 1994;90:8-18
30. Cyberonics' VNS Therapy surpasses 100,000 patient years of experience [press release]. Houston, Tex: Cyberonics, Inc; August 22, 2005. Available at: http://www.keepmedia.com/pubs/PRNewswire/2005/08/22/975347. Accessibility verified May 31, 2006
31. Amar AP, Heck CN, Levy ML, et al. An institutional experience with cervical vagus nerve trunk stimulation for medically refractory epilepsy: rationale, technique, and outcome. Neurosurgery 1998;43:1265-1276; discussion 1276-1280
32. Mohs RC, Cohen L. Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull 1988;24:627-628
33. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
34. Montgomery SA, Smeyatsky N, de Ruiter M, et al. Profiles of antidepressant activity with the Montgomery-Asberg Depression Rating Scale. Acta Psychiatr Scand Suppl 1985;320:38-42
35. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996;26:477-486
36. Gottfries CG, Brane G, Gullberg B, et al. A new rating scale for dementia syndromes. Arch Gerontol Geriatr 1982;1:311-330
37. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), 1: conceptual framework and item selection. Med Care 1992;30:473-483
38. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S22-S32
39. Blennow K, Fredman P, Wallin A, et al. Protein analyses in cerebrospinal fluid 1: influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur Neurol 1993;33:126-128
40. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders, 1: establishment of reference values. Scand J Clin Lab Invest 1977;37:385-390
41. Blennow K, Wallin A, Agren H, et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995;26:231-245
42. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52
43. Vanderstichele H, Blennow K, D'Heuvaert N, et al. Development of a specific diagnostic test for measurement of β-amyloid(1-42) in CSF. In: Fisher A, Hanin I, Yoshida M, eds. Progress in Alzheimer's and Parkinson's Diseases. New York, NY: Plenum Press; 1998:773-778
44. Risberg J. Regional cerebral blood flow measurements by 133Xe-inhalation: methodology and applications in neuropsychology and psychiatry. Brain Lang 1980;9:9-34
45. Wiig EH, Nielsen NP, Minthon L, et al. Parietal lobe activation in rapid, automatized naming by adults. Percept Mot Skills 2002;94:1230-1244
46. Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006;10:1-160
47. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005;58:347-354
48. Ben-Menachem E, Manon-Espaillat R, Ristanovic R, et al. Vagus nerve stimulation for treatment of partial seizures 1: a controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group. Epilepsia 1994;35:616-626